VolumeVol. 56 • Number No. 4 • October - December 2018 Back
Original Article
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0
International License, which permits use, share — copy and redistribute the material in any medium or format,
adapt — remix, transform, and build upon the material, as long as you give appropriate credit,
provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner,
but not in any way that suggests the licensor endorses you or your use. You may not use the material for
commercial purposes. If you remix, transform, or build upon the material, you must distribute your
contributions under the same license as the original. You may not apply legal terms or technological
measures that legally restrict others from doing anything the license permits. The images or other
third party material in this article are included in the article’s Creative Commons license, unless indicated
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons
license and your intended use is not permitted by statutory regulation or exceeds the permitted use,
you will need to obtain permission directly from the copyright holder. To view a copy of this license,
visit https://creativecommons.org/licenses/by-nc-sa/4.0/.
Treatment Efficacy and Risk of Bleeding Among Cancer Patients Treated for Venous Thromboembolism with Dabigatran Compared to Warfarin
Authors: Jay Malvin Tia, Joiane Cris Casapao, Wilfredo Liangco, Emma Gaspar-Trinidad
DOI: 10.65564/pjim.19556baf0f
Date of Publication: December 2018
More Details
Authors and Affiliations:
Jay Malvin Tia,M.D.*; Joiane Cris Casapao, M.D.*; Wilfredo Liangco, M.D.**;and Emma Gaspar-Trinidad, M.D.**
*Jay Malvin Tia and Joiane Cris Casapao are independent authors not affiliated with any institution currently
**Manila Medical Center, Manila, Philippines
Corresponding author: Jay Malvin Tia, M.D.
Email: [email protected]
License
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0
International License, which permits use, share — copy and redistribute the material in any medium or format,
adapt — remix, transform, and build upon the material, as long as you give appropriate credit,
provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner,
but not in any way that suggests the licensor endorses you or your use. You may not use the material for
commercial purposes. If you remix, transform, or build upon the material, you must distribute your
contributions under the same license as the original. You may not apply legal terms or technological
measures that legally restrict others from doing anything the license permits. The images or other
third party material in this article are included in the article’s Creative Commons license, unless indicated
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons
license and your intended use is not permitted by statutory regulation or exceeds the permitted use,
you will need to obtain permission directly from the copyright holder. To view a copy of this license,
visit https://creativecommons.org/licenses/by-nc-sa/4.0/.